 trial doxorubicin bisantrene mitoxantrone advanced breast cancer Southwest Oncology Group study women metastatic breast cancer doxorubicin patients bisantrene patients mitoxantrone patients doses weeks cross-over design relative efficacy toxicity eligible patients previous chemotherapy regimen patients estrogen receptor positive endocrine therapy patients assessable response assessable toxic effects median age years premenopausal perimenopausal Visceral dominant disease present patients Ninety-seven percent patients disease-free interval diagnosis first recurrence year response rate doxorubicin bisantrene mitoxantrone Median time treatment failure days doxorubicin days bisantrene days mitoxantrone logrank median survival days doxorubicin days bisantrene days mitoxantrone logrank survival years similar agents responses patients response patients patients mitoxantrone patients Toxicity discontinuance therapy common doxorubicin discontinuance therapy due request cardiotoxicity major dose-limiting toxic effect agents Nausea vomiting mucositis alopecia severe doxorubicin Congestive heart failure patients doxorubicin patients bisantrene patients mitoxantrone decrease left ventricular ejection fraction moderate Alexander grade changes common patients doxorubicin doxorubicin-treated patients bisantrene-treated patients mitoxantrone-treated patients study bisantrene mitoxantrone modest activity metastatic breast carcinoma activity doxorubicin agents cost increased toxicity